脳卒中後の心臓炎症の MR 証拠 (MIRACLE)
脳卒中後の心臓炎症の磁気共鳴画像証拠
The present study is an investigator initiated, single-centre, prospective, proof-of-concept cohort study aiming to enroll 44 patients with acute middle cerebral artery (MCA) ischemic stroke, involving the right (n=22) and left (n=22) MCA territories and 24 control patients with acute focal neurological symptoms but no evidence of acute brain infarct on DWI-MRI.
調査の概要
状態
詳細な説明
The present study is an investigator-initiated, single-center, prospective cohort study. The study aims to enroll 44 patients with acute/subacute middle cerebral artery (MCA) ischemic stroke. The investigators will compare inflammatory markers among 44 patients with MCA ischemic stroke within 10 days post-stroke vs. 60±15 days post-stroke. Other measures to be determined at both time points include B-Type Natriuretic Peptide and systemic inflammatory markers.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Diana Ayan, MSc
- 電話番号：35826 +1 519.685.8500
- メール：diana.ayan@lhsc.on.ca
研究連絡先のバックアップ
- 名前：Jennifer Moussa
- 電話番号：33110 +1 519.685.8500
- メール：jennifer.moussa@lhsc.on.ca
研究場所
-
-
Ontario
-
London、Ontario、カナダ、N6A 5A5
- 募集
- Heart & Brain Lab, Western University
-
主任研究者：
- Luciano Sposato, MD, MBA
-
コンタクト：
- Jennifer Moussa
- 電話番号：33110 +1(519) 685-8500
- メール：jennifer.moussa@lhsc.on.ca
-
コンタクト：
- Diana Ayan, MSc
- 電話番号：35826 +1(519) 685-8500
- メール：diana.ayan@lhsc.on.ca
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The investigators will include 44 patients with right (n=22) and left (n=22) MCA ischemic stroke. The investigators aim to include at least 50% of female patients. The investigators will include 24 participants in a control group. Participants in the control group will be patients presenting with acute stroke symptoms but no evidence of acute brain infarction on DWI-MRI imaging. Participants will be divided by sex: the investigators aim to enroll 12 female and 12 male participants. The investigators will aim to enroll participants within the same age range as the stroke participants.
説明
Inclusion Criteria:
• Acute ischemic stroke in the right or left MCA territory. Acute ischemic stroke is defined as acute onset focal symptoms matching an acute brain infarct documented on Head computed tomography or diffusion-weighted imaging (DWI) MRI of the brain showing restricted diffusion.
Exclusion Criteria:
- History of known atrial fibrillation, prior myocardial infarction, coronary artery disease, heart failure, prior cardiovascular surgery or percutaneous intervention.
- Previous stroke (occurred within 3 months before the index event)
- Impaired renal function defined as a creatinine clearance <97 mL/min in men or <88 mL/min in women, according to the Cockcroft formula.
- hs-TnT >100 on routine acute stroke baseline bloodwork upon admission.
- Clinically or neurologically unstable patients as per the treating physician.
- Ongoing infection or recent infection within the previous 3 months
- Surgery within 3 months before the stroke
- Concurrent and active inflammatory conditions (connective tissue diseases, rheumatological disease, etc.) or use of anti-inflammatory medications
- Pregnancy, Stage IV renal insufficiency, eGFR <30, and any other contraindications to the use of gadolinium.
- Stroke with symptomatic hemorrhagic transformation
- Subjects will be excluded if they fail the LHSC standard MRI screening questionnaire (cardiac pacemakers/wires, aneurysm clips, shunt/surgical clips, shrapnel/bullets, dentures or metal braces, intra-uterine devices, heart valves, ear implants, prostheses, medication patches such as Nicoderm, Habitrol, or Transderm-Nitro, claustrophobia, history of a head or eye injury involving metal fragments.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：COHORT
- 時間の展望：PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Cases (Ischemic stroke): Left and right middle cerebral artery ischemic stroke
Patients presenting with acute onset focal neurological deficits and DWI-MRI evidence of an acute brain infarct of the left or right middle cerebral artery ischemic stroke. |
Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis. Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days. Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days. |
|
Controls (TIA): Patients with acute focal neurological symptoms without brain infarct on MRI.
Patients presenting with acute onset focal neurological deficits presumed to be of vascular origin, WITHOUT DWI-MRI evidence of an acute brain infarct. |
Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis. Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days. Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The severity of left ventricular myocardial inflammation on cardiac MRI within 10 days post-stroke
時間枠：Within 10 days of stroke onset
|
Proportion of left ventricular myocardium showing inflammatory changes on gadolinium-enhanced cardiac MRI |
Within 10 days of stroke onset
|
|
The extent of left ventricular fibrosis measured on gadolinium-enhanced cardiac MRI within 10 days of stroke onset
時間枠：Within 10 days of stroke onset
|
Proportion of left ventricular myocardium showing fibrosis on gadolinium-enhanced cardiac MRI |
Within 10 days of stroke onset
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in left ventricular inflammation measured on gadolinium-enhanced cardiac MRI at 10 and 60±15 days post-stroke
時間枠：At 60±15 days compared to first 10 days
|
Quantification of left ventricular inflammation measured on gadolinium-enhanced cardiac MRI |
At 60±15 days compared to first 10 days
|
|
Change in B-Type Natriuretic Peptide (NT-proBNP) levels in the second measurement performed at 60±15 days post-stroke relative to the plasma sample drawn within 10 days.
時間枠：At 60±15 days compared to first 10 days
|
Change in levels of NT-proBNP between 10 and 60±15 days post-stroke |
At 60±15 days compared to first 10 days
|
|
Change in systemic inflammatory markers between 10 and 60±15 days post-stroke
時間枠：At 60±15 days compared to first 10 days
|
High-performance protein biomarker panel for following 92 inflammatory biomarkers in pg/mL ADA; ARTN; AXIN1; NGF; CCL13; CCL19; CCL2; CCL20; CCL23; CCL25; CCL28; CCL3; CCL4; CCL7; CCL8; CXCL10; CXCL11; CXCL5; CXCL6; CXCL9; CDCP1; CASP8; CST5; DNER; CCL11; EIF4EBP1; FGF19; FGF21; FGF23; FGF5; FLT3LG; CX3CL1; GDNF; CXCL1; HGF; IFNG; IL1A; IL10; IL10RA; IL10RB; IL12B; IL13; IL15RA; IL17A; IL17C; IL18; IL18R1; IL2; IL2RB; IL20; IL20RA; IL22RA1; IL24; IL33; IL4; IL5; IL6; IL7; CXCL8; MMP1; KITLG; LIF; LIFR; LTA; CSF1; SIRT2; CD244;NTF3;NRTN;OSM;CD274;S100A12;TGFA;STAMBP;SLAMF1;MMP10;SULT1A1;CD6;CD5;CD8A;TSLP;TGFB1;TNF;TNFSF10;TNFSF11;TNFSF12;TNFSF14;TNFRSF11B;CD40;TNFRSF9;PLAU;VEGFA |
At 60±15 days compared to first 10 days
|
|
Changes in left atrial inflammation measured on gadolinium-enhanced cardiac MRI at 10 and 60±15 days post-stroke
時間枠：At 60±15 days compared to first 10 days
|
Quantification of left atrial inflammation measured on gadolinium-enhanced cardiac MRI |
At 60±15 days compared to first 10 days
|
|
Changes in left atrial fibrosis measured on gadolinium-enhanced cardiac MRI at 10 and 60±15 days post-stroke
時間枠：At 60±15 days compared to first 10 days
|
Quantification of left atrial fibrosis measured on gadolinium-enhanced cardiac MRI |
At 60±15 days compared to first 10 days
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Luciano Sposato, MD、London Health Sciences Center, Western University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。